Dr Ayman Sahli first obtained his Ph.D. in Organic Chemistry in 1993 from the University of Nebraska in the USA. He conducted post doctoral research at the University of Delaware in total synthesis of anti cancer products.
Having started his career in scale-up and commercial research, Dr Sahli completed further studies in research and development, adding to his list of expertise. His work has also been the subject of several publications.
Dr Sahli joined Hikma Pharmaceuticals in 2004, and was appointed Deputy General Manager, a post he held until 2008, before joining Julphar as General Manager. He was soon appointed Chief Executive Officer and is today leading Julphar through a rapid phase of growth and development, including the diversification of conventional medicine to biosimilar production and international manufacturing expansion.